First Mesothelioma Therapeutic Approved in 16 Years
The FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
The FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
The FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
Read MoreThe US Food and Drug Administration (FDA) approved the combination of nivolumab plus ipilimumab as a first-line treatment for patients with certain lung cancers.
Read MoreThe US FDA has approved Nivolumab (Opdivo), the first immunotherapy to be available for use in the treatment of lung cancer.
Read More